Strata Critical Medical (SRTA) Price Target Raised by 18.09% to $9.44
Price Target Update: The average one-year price target for Strata Critical Medical (NasdaqCM:SRTA) has been revised to $9.44 per share, reflecting an 18.09% increase from the previous estimate of $7.99, with a potential range from $7.32 to $11.81 per share.
ARK Investment Management Holdings: ARK Investment Management has reduced its holdings in SRTA from 8,600K shares to 6,405K shares, a decrease of 34.27%, while ARKQ and ARKX ETFs have increased their allocations by 8.50% and 22.43%, respectively.
Other Shareholders: Third Point holds 5,000K shares (5.79% ownership), and AWM Investment has increased its holdings slightly to 2,821K shares (3.27% ownership).
Fintel Overview: Fintel provides comprehensive investment research data, including fundamentals, analyst reports, and ownership data, aimed at individual investors and small hedge funds.
Trade with 70% Backtested Accuracy
Analyst Views on SRTA
About SRTA
About the author
Strata Secures $30 Million Credit Facility to Support Acquisitions
- Credit Agreement Secured: Strata Critical Medical has entered into a secured asset-based revolving credit agreement with JPMorgan Chase Bank for up to $30 million, which can be increased to $50 million under certain conditions, significantly enhancing the company's capital efficiency to support its acquisition strategy in the organ transplant industry.
- Increased Financial Flexibility: By excluding its owned aircraft fleet from the collateral package, Strata maintains significant optionality for future financing, a strategy that not only optimizes cash utilization but also provides the company with more financial choices.
- Continued Acquisition Strategy: With a strong track record of successful tuck-in acquisitions in the clinical perfusion space, this new credit facility will enable Strata to continue executing its proven growth strategy, thereby accelerating business expansion and enhancing market competitiveness.
- Industry Leadership: As a critical logistics and medical services provider to the U.S. healthcare industry, Strata operates one of the nation's largest air transport and surgical services networks, and its integrated
Major Stocks Including BlackBerry, FedEx, and Nike Decline in Friday's Pre-Market Trading
U.S. Stock Futures: U.S. stock futures are mostly higher, with Nasdaq 100 futures gaining around 100 points on Friday.
BlackBerry Earnings Report: BlackBerry Ltd reported third-quarter revenue of $141.8 million, exceeding analyst expectations, but shares fell 4.6% in pre-market trading.
Other Stocks Declining: Several stocks, including Aimei Health Technology and Nike Inc, experienced significant declines in pre-market trading despite some reporting better-than-expected earnings.
Market Overview: The overall market sentiment is cautious, with various stocks showing downward trends following recent earnings reports and inflation data.
Oracle Shares Rise Over 5%; Check Out 20 Stocks Making Moves in Premarket Trading
Oracle's Stock Surge: Oracle Corp's shares rose 5.7% in pre-market trading following TikTok's announcement of a new U.S. entity formed with investors including Oracle, with the deal expected to close on January 22.
Pre-Market Gainers: Several stocks saw significant gains in pre-market trading, including Vision Marine Technologies (up 48.7%), Inspire Veterinary Partners (up 32.2%), and WhiteFiber Inc (up 18.2%).
Pre-Market Losers: Notable declines were observed in pre-market trading for Zeta Network Group (down 29.4%), cbdMD Inc (down 19.2%), and Aimei Health Technology (down 15.8%).
Nike's Performance: Nike Inc's shares dipped 9.9% despite reporting better-than-expected earnings and sales, attributed to a decline in gross margins for the second consecutive quarter.
Strata Appoints Will Cook to Board, Enhancing Organ Transplant Services
- New Board Member: Strata Critical Medical has appointed Will Cook to its Board of Directors, effective December 3, 2025, aiming to leverage his extensive healthcare experience to scale the company's organ recovery and logistics platform nationwide.
- Rich Leadership Experience: Will Cook, previously President and CEO of Vail Health, brings deep industry relationships from a nonprofit community healthcare system in Colorado, which will provide invaluable resources to Strata in its mission to increase organ transplant numbers.
- Support for Strategic Development: Cook's leadership at the University of Colorado Hospital included major facility development projects, showcasing his strategic vision in healthcare services that will aid Strata in executing its multi-pronged growth strategy.
- Solid Educational Background: Will Cook holds a master's degree in health administration from Washington University School of Medicine and a Bachelor of Arts in Business Administration from Texas A&M University, further enhancing his expertise in the healthcare sector and laying a strong foundation for Strata's future growth.
Strata Appoints Will Cook to Board, Enhancing Organ Transplant Services
- New Board Member: Strata Critical Medical has appointed Will Cook to its Board, aiming to leverage his extensive healthcare experience to expand the company's organ recovery and logistics platform nationwide.
- Strategic Committee Appointment: Cook will also serve on the Compensation and Nominating and Corporate Governance Committees, which is expected to enhance the professionalism and transparency of the company's governance structure.
- Industry Background Advantage: Having previously served as CEO of University of Colorado Hospital, where he led major facility development projects, Cook's deep relationships in the healthcare sector will provide invaluable resources to support Strata's growth strategy.
- Diverse Growth Strategy: Cook expressed his commitment to executing the company's multi-pronged growth strategy, further advancing the life-saving work of organ transplantation services, highlighting Strata's mission in the medical services sector.
Strata Critical Medical (SRTA) Price Target Raised by 18.09% to $9.44
Price Target Update: The average one-year price target for Strata Critical Medical (NasdaqCM:SRTA) has been revised to $9.44 per share, reflecting an 18.09% increase from the previous estimate of $7.99, with a potential range from $7.32 to $11.81 per share.
ARK Investment Management Holdings: ARK Investment Management has reduced its holdings in SRTA from 8,600K shares to 6,405K shares, a decrease of 34.27%, while ARKQ and ARKX ETFs have increased their allocations by 8.50% and 22.43%, respectively.
Other Shareholders: Third Point holds 5,000K shares (5.79% ownership), and AWM Investment has increased its holdings slightly to 2,821K shares (3.27% ownership).
Fintel Overview: Fintel provides comprehensive investment research data, including fundamentals, analyst reports, and ownership data, aimed at individual investors and small hedge funds.
Strata Secures $30 Million Credit Facility to Support Acquisitions
- Credit Agreement Secured: Strata Critical Medical has entered into a secured asset-based revolving credit agreement with JPMorgan Chase Bank for up to $30 million, which can be increased to $50 million under certain conditions, significantly enhancing the company's capital efficiency to support its acquisition strategy in the organ transplant industry.
- Increased Financial Flexibility: By excluding its owned aircraft fleet from the collateral package, Strata maintains significant optionality for future financing, a strategy that not only optimizes cash utilization but also provides the company with more financial choices.
- Continued Acquisition Strategy: With a strong track record of successful tuck-in acquisitions in the clinical perfusion space, this new credit facility will enable Strata to continue executing its proven growth strategy, thereby accelerating business expansion and enhancing market competitiveness.
- Industry Leadership: As a critical logistics and medical services provider to the U.S. healthcare industry, Strata operates one of the nation's largest air transport and surgical services networks, and its integrated
Major Stocks Including BlackBerry, FedEx, and Nike Decline in Friday's Pre-Market Trading
U.S. Stock Futures: U.S. stock futures are mostly higher, with Nasdaq 100 futures gaining around 100 points on Friday.
BlackBerry Earnings Report: BlackBerry Ltd reported third-quarter revenue of $141.8 million, exceeding analyst expectations, but shares fell 4.6% in pre-market trading.
Other Stocks Declining: Several stocks, including Aimei Health Technology and Nike Inc, experienced significant declines in pre-market trading despite some reporting better-than-expected earnings.
Market Overview: The overall market sentiment is cautious, with various stocks showing downward trends following recent earnings reports and inflation data.
Oracle Shares Rise Over 5%; Check Out 20 Stocks Making Moves in Premarket Trading
Oracle's Stock Surge: Oracle Corp's shares rose 5.7% in pre-market trading following TikTok's announcement of a new U.S. entity formed with investors including Oracle, with the deal expected to close on January 22.
Pre-Market Gainers: Several stocks saw significant gains in pre-market trading, including Vision Marine Technologies (up 48.7%), Inspire Veterinary Partners (up 32.2%), and WhiteFiber Inc (up 18.2%).
Pre-Market Losers: Notable declines were observed in pre-market trading for Zeta Network Group (down 29.4%), cbdMD Inc (down 19.2%), and Aimei Health Technology (down 15.8%).
Nike's Performance: Nike Inc's shares dipped 9.9% despite reporting better-than-expected earnings and sales, attributed to a decline in gross margins for the second consecutive quarter.
Strata Appoints Will Cook to Board, Enhancing Organ Transplant Services
- New Board Member: Strata Critical Medical has appointed Will Cook to its Board of Directors, effective December 3, 2025, aiming to leverage his extensive healthcare experience to scale the company's organ recovery and logistics platform nationwide.
- Rich Leadership Experience: Will Cook, previously President and CEO of Vail Health, brings deep industry relationships from a nonprofit community healthcare system in Colorado, which will provide invaluable resources to Strata in its mission to increase organ transplant numbers.
- Support for Strategic Development: Cook's leadership at the University of Colorado Hospital included major facility development projects, showcasing his strategic vision in healthcare services that will aid Strata in executing its multi-pronged growth strategy.
- Solid Educational Background: Will Cook holds a master's degree in health administration from Washington University School of Medicine and a Bachelor of Arts in Business Administration from Texas A&M University, further enhancing his expertise in the healthcare sector and laying a strong foundation for Strata's future growth.
Strata Appoints Will Cook to Board, Enhancing Organ Transplant Services
- New Board Member: Strata Critical Medical has appointed Will Cook to its Board, aiming to leverage his extensive healthcare experience to expand the company's organ recovery and logistics platform nationwide.
- Strategic Committee Appointment: Cook will also serve on the Compensation and Nominating and Corporate Governance Committees, which is expected to enhance the professionalism and transparency of the company's governance structure.
- Industry Background Advantage: Having previously served as CEO of University of Colorado Hospital, where he led major facility development projects, Cook's deep relationships in the healthcare sector will provide invaluable resources to support Strata's growth strategy.
- Diverse Growth Strategy: Cook expressed his commitment to executing the company's multi-pronged growth strategy, further advancing the life-saving work of organ transplantation services, highlighting Strata's mission in the medical services sector.
Strata Critical Medical (SRTA) Price Target Raised by 18.09% to $9.44
Price Target Update: The average one-year price target for Strata Critical Medical (NasdaqCM:SRTA) has been revised to $9.44 per share, reflecting an 18.09% increase from the previous estimate of $7.99, with a potential range from $7.32 to $11.81 per share.
ARK Investment Management Holdings: ARK Investment Management has reduced its holdings in SRTA from 8,600K shares to 6,405K shares, a decrease of 34.27%, while ARKQ and ARKX ETFs have increased their allocations by 8.50% and 22.43%, respectively.
Other Shareholders: Third Point holds 5,000K shares (5.79% ownership), and AWM Investment has increased its holdings slightly to 2,821K shares (3.27% ownership).
Fintel Overview: Fintel provides comprehensive investment research data, including fundamentals, analyst reports, and ownership data, aimed at individual investors and small hedge funds.
